Opioid — Number of open cases
Products & Services · Number of open casesJohnson & Johnson Opioid — Number of open cases increased by 85.7% to -$5.00 in Q3 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ3 2025
How to read this metric
An increase indicates rising legal activity and potential for future financial impact, while a decrease signals a reduction in active litigation volume.
Detailed definition
The count of active legal proceedings or lawsuits currently being litigated in court regarding opioid products. This met...
Peer comparison
Standard metric for companies involved in multi-district litigation or class action lawsuits.
Metric ID:
jnj_segment_opioid_number_of_open_casesHistorical Data
3 periods
| Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|
| Value | $325.00 | -$35.00 | -$5.00 |
| QoQ Change | — | -110.8% | +85.7% |
Range-$35.00 – $325.00
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's opioid — number of open cases?
- Johnson & Johnson (JNJ) reported opioid — number of open cases of -$5.00 in Q3 2025.
- What does opioid — number of open cases mean?
- The number of active, ongoing lawsuits the company is currently defending in court.